BioWorld Asia

April 30, 2003

Diatos Licenses European Rights To Cancer Drug From Medarex

PARIS - Diatos SA and Medarex Inc. signed a licensing agreement giving Diatos exclusive European rights to develop and commercialize a potential new cancer treatment. (BioWorld International) Read More

Biotech Groups In Norway Unite, Plan To Catch Up With Neighbors

Genetic Study Of Clotting Enzyme Points To 'Fantastic' Drug Target

Curnock Cook Investing Again After Forming New €150M Fund

No Abstract Read More

PPL Gives Up Plans On Plant To Manufacture AAT Product

French Companies, Agency Unite For Effort In America

Alizyme Eyes Phase III, Alliance Following Renzapride Results

GenoWay Raises EUR3.3M To Fund Work On Animal, In Vitro Models

Merck Stops Development Of Celltech PDE-4 Inhibitor

UK Industry Gathers To Celebrate 50th Anniversary Of DNA Finding

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 6, 2026.

Depression concept with human, broken brain and heavy rain

CROI 2026 highlights depression and cognitive vulnerability in HIV

BioWorld

The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 3, 2026

University of Southern California reports new MAPT aggregation inhibitors

BioWorld Science

The University of Southern California has identified (2-oxo-2H-chromen-3-yl) scaffold-based carboxamide analogues acting as potent microtubule-associated protein...

Tanycytes in green capturing tau protein in red.

Brain’s hidden tau-clearing pathway uncovered

BioWorld Science

Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...